Overview

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Terminated

Trial end date:
2016-04-27

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Albumin-Bound Paclitaxel
Idelalisib
Paclitaxel